Anebulo Pharmaceuticals, Inc. (ANEB) quarterly balance sheet — complete assets, liabilities & equity history
| Total Current Assets | 9.27M | 10.54M | 11.96M | 13.81M | 15.4M | 1.96M | 3.51M | 5.37M | 6.82M | 9.05M | 11.67M | 14.43M |
| Cash & Short-Term Investments | 9.04M | 10.35M | 11.63M | 13.28M | 15M | 1.4M | 3.09M | 5.15M | 6.64M | 8.52M | 11.25M | 14.16M |
| Cash Only | 9.04M | 10.35M | 11.63M | 13.28M | 15M | 1.4M | 3.09M | 5.15M | 6.64M | 8.52M | 11.25M | 14.16M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 56.78K | 9.82K | 0 | 0 | 30.76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 73.22K | 0 | 0 | 245.36K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 148.23K | 165.67K | 183.11K | 200.55K | 445.73K | 505.43K | 565.12K | 624.82K | 684.52K | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 148.23K | 165.67K | 183.11K | 200.55K | 445.73K | 505.43K | 565.12K | 624.82K | 684.52K | 0 | 0 | 0 |
| Total Assets | 9.42M | 10.7M | 12.15M | 14.01M | 15.84M | 2.47M | 4.07M | 6M | 7.5M | 9.05M | 11.67M | 14.43M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -40.52% | 333.6% | 198.19% | 133.64% | 111.19% | -72.72% | -65.1% | -58.46% | -55.59% | -54.34% | -25.09% | -16.33% |
| Total Current Liabilities | 554.86K | 607.54K | 487.69K | 546.03K | 878.8K | 569.23K | 260.58K | 1.01M | 1.01M | 716.56K | 1.07M | 1.49M |
| Accounts Payable | 554.86K | 607.54K | 224.18K | 427.58K | 319.51K | 252.14K | 156.43K | 384.92K | 318.68K | 565.95K | 534.54K | 570.9K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -407.85K | -356.28K | 0 | 0 | 422.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 16.71x | 17.34x | 24.53x | 25.29x | 17.52x | 3.45x | 13.46x | 5.32x | 6.73x | 12.63x | 10.92x | 9.68x |
| Quick Ratio | 16.71x | 17.34x | 24.53x | 25.29x | 17.52x | 3.45x | 13.46x | 5.32x | 6.73x | 12.63x | 10.92x | 9.68x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 930.78K | 356.28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 930.78K | 356.28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.49M | 963.82K | 487.69K | 546.03K | 878.8K | 569.23K | 260.58K | 1.01M | 1.01M | 716.56K | 1.07M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -9.04M | -10.35M | -11.63M | -13.28M | -15M | -1.4M | -3.09M | -5.15M | -6.64M | -8.52M | -11.25M | -14.16M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -150.23x | -122.77x | -121.99x | -5.84x | -40.25x | -35.86x | -21.61x | -26.70x | -84.35x | - | - | - |
| Total Equity | 7.94M | 9.74M | 11.66M | 13.46M | 14.96M | 1.9M | 3.81M | 4.99M | 6.49M | 8.33M | 10.6M | 12.94M |
| Equity Growth % | -46.96% | 412.83% | 205.78% | 170.04% | 130.64% | -77.21% | -64.04% | -61.48% | -58.19% | -56.42% | -29.64% | -24.59% |
| Book Value per Share | 0.19 | 0.24 | 0.28 | 0.49 | 0.55 | 0.07 | 0.15 | 0.19 | 0.25 | 0.33 | 0.42 | 0.50 |
| Total Shareholders' Equity | 7.94M | 9.74M | 11.66M | 13.46M | 14.96M | 1.9M | 3.81M | 4.99M | 6.49M | 8.33M | 10.6M | 12.94M |
| Common Stock | 41.09K | 41.09K | 41.09K | 41.09K | 41.09K | 25.93K | 25.93K | 25.93K | 25.93K | 25.63K | 25.63K | 25.63K |
| Retained Earnings | -78.05M | -76.05M | -73.89M | -71.74M | -70.07M | -67.6M | -65.4M | -64.05M | -62.4M | -59.68M | -57.2M | -54.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |